InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
64,342.47
(
2.31%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: adreamer post# 22501

Saturday, 09/29/2012 7:06:11 PM

Saturday, September 29, 2012 7:06:11 PM

Post# of 80490
Berger may have been referring to the fact that while they plan to run a treatment naive ALK+ cohort (potentially 1st line), in EGFR they are targeting 2nd line pts who are resistant to at least one prior EGFR inhibitor. http://1.usa.gov/UA4RlT

Hopefully we'll learn more tmrw morning but one thing to note is that even in 2nd line EGFR represents about 2X the ROS1 and ALK+ pts.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up